Financial Performance - Revenue for the six months ended September 30, 2025, was RMB 806,579,000, an increase from RMB 746,509,000 for the same period in 2024, representing a growth of approximately 8%[3] - Gross profit for the same period was RMB 73,727,000, compared to RMB 19,516,000 in 2024, indicating a significant improvement[3] - Net profit for the six months ended September 30, 2025, was RMB 1,883,489,000, a turnaround from a loss of RMB 1,354,773,000 in 2024[4] - Basic and diluted earnings per share for the period were RMB 68.50, compared to a loss of RMB 46.80 per share in the previous year[4] - Other income and gains for the period amounted to RMB 2,302,859,000, up from RMB 299,156,000 in 2024[3] - Total comprehensive income for the six months was RMB 1,994,817,000, compared to a loss of RMB 1,321,453,000 in the same period last year[5] Cost Management - The company reported a decrease in administrative and other operating expenses to RMB 81,286,000 from RMB 115,351,000 in the previous year, reflecting improved cost management[3] - Financial expenses decreased to RMB 69,997,000 from RMB 85,447,000, indicating better financial efficiency[3] Asset and Liability Management - As of September 30, 2025, total non-current assets amounted to RMB 1,933,304,000, an increase from RMB 1,639,690,000 as of March 31, 2025, reflecting a growth of approximately 18%[6] - Current assets totaled RMB 8,279,542,000, significantly higher than RMB 3,327,474,000 reported on March 31, 2025, indicating a growth of over 148%[6] - Total liabilities reached RMB 9,409,989,000, compared to RMB 2,576,524,000 in the previous period, marking an increase of approximately 265%[6] - The company's net asset value was reported at RMB 2,067,698,000, a substantial increase from RMB 397,102,000 as of March 31, 2025[7] Business Segments Performance - The medical and pharmaceutical retail segment generated revenue of RMB 70,714 thousand, a decrease of 1.2% from RMB 72,615 thousand in the previous year[17] - The e-commerce and distribution segment reported revenue of RMB 427,727 thousand, an increase of 37% from RMB 312,047 thousand in the prior period[17] - The property investment and management segment achieved revenue of RMB 2,533,709 thousand, significantly up from RMB 590,281 thousand, marking an increase of approximately 329%[17] Strategic Initiatives - The company plans to continue expanding its market presence and investing in new product development to sustain growth[2] - The company is focusing on expanding its e-commerce capabilities and enhancing its product offerings in the medical retail sector[15] - Future outlook includes continued investment in property development and management to leverage market opportunities[15] - The company is exploring potential mergers and acquisitions to enhance its market position and expand its operational footprint[15] Shareholder Value and Equity - The total equity attributable to the owners of the company was RMB 734,787,000, a significant recovery from a loss of RMB 1,256,206,000 in the previous period[7] - The company reported a net profit attributable to shareholders of RMB 1,875,231 thousand for the six months ended September 30, 2025, compared to a loss of RMB (1,265,687) thousand for the same period in 2024[40] - Basic and diluted earnings per share attributable to shareholders were RMB 0.685, compared to a loss of RMB 0.468 for the same period last year[78] Market Trends and Economic Environment - In the first three quarters of 2025, China's GDP reached RMB 97.1 trillion, growing by 5.2% year-on-year[57] - The total retail sales of consumer goods in China amounted to RMB 36.6 trillion, with a year-on-year increase of 4.5%[57] - Online retail sales exceeded RMB 11.3 trillion, representing a year-on-year growth of 9.8%, which is approximately double the overall consumption market growth rate[61] Corporate Governance and Compliance - The company is committed to maintaining high corporate governance standards and has adhered to all corporate governance code provisions during the reporting period[126] - The audit committee has reviewed the accounting policies and interim financial statements for the six months ending September 30, 2025[127] Share Option Plan - The 2023 Share Option Plan allows for the issuance of up to 10% of the total shares issued as of the adoption date, equating to 912,966,911 shares[50] - A total of 600,000,000 share options were granted to employees under the 2023 Share Option Plan, allowing for the subscription of 600,000,000 shares[51] - The exercise price for the share options is set at HKD 0.101 per share, subject to adjustment due to a capital reorganization[52]

Core Viewpoint - Beijing Resources (00618) anticipates a profit of approximately RMB 1.8 billion to RMB 2 billion for the six months ending September 30, 2025, contrasting with a loss of about RMB 1.355 billion for the six months ending September 30, 2024 [1] Group Summary - The expected profit is primarily due to the planned injection of the entire equity of its wholly-owned subsidiary, Antai International Investment Group (Hong Kong) Limited, into a partnership, which is expected to generate a sale revenue of approximately RMB 2.314 billion [1] - The transaction involves the sale of 16 subsidiaries, six of which are engaged in property development in China [1] - Following the completion of the transaction, the company will no longer hold any real estate development projects in progress, leading to a significant reduction in related financial costs and anticipated liability provisions [1]

Core Viewpoint - The company expects to achieve a profit of approximately RMB 1.8 billion to RMB 2 billion for the six months ending September 30, 2025, compared to a loss of approximately RMB 1.355 billion for the six months ending September 30, 2024 [1] Group 1: Financial Performance - The anticipated profit is primarily due to the planned injection of the entire equity of its wholly-owned subsidiary, Antai International Investment Group (Hong Kong) Limited, into a partnership, which is expected to generate a sale revenue of approximately RMB 2.314 billion [1] - The company will no longer hold any real estate development projects under development after the completion of the aforementioned transaction, leading to a significant reduction in related financial costs and expected liability provisions [1]

Core Viewpoint - The company, North China Resources (00618.HK), anticipates a profit of approximately RMB 1.8 billion to RMB 2 billion for the six months ending September 30, 2025, following a loss of about RMB 1.355 billion for the six months ending September 30, 2024 [1] Financial Performance - The expected profit is primarily due to the planned injection of the entire equity of its wholly-owned subsidiary, Antai International Investment Group (Hong Kong) Limited, into a partnership, which is projected to generate a sale revenue of approximately RMB 2.314 billion [1] - After the completion of the aforementioned transaction, the company will no longer hold any real estate development projects in progress, leading to a significant reduction in financial costs and expected liability provisions associated with the sold group [1]

北大資源（控股）有限公司 Peking University Resources (Holdings) Company Limited （於百慕達註冊成立之有限公司） （股份代號：00618） 正面盈利預告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 本 公 司 股 東 及 潛 在 投 資 者 於 買 賣 本 公 司 證 券 時 務 請 審 慎 行 事。 承董事會命 北 大 資 源（控 股）有 限 公 司 主 席 黃啓豪 本 公 告 由 北 大 資 源（控 股）有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」） 根據香港聯合交易所有限公司證券上市規則第13.09條 及 證 券 及 期 貨 條 例（香 港 法例第571章）第XIVA部 之 內 幕 消 息 條 文 而 作 出。 本 公 司 董 事 會（「董事會」）謹 此 知 會 本 公 司 股 東（「股 東」）及 潛 在 ...

Core Viewpoint - The company has established an Artificial Intelligence Medical Advisory Committee to provide strategic guidance and expert insights for the development of its AI-driven digital health platform, Lets Go, reflecting its commitment to building a preventive healthcare ecosystem in emerging markets [1] Group 1 - The newly formed advisory committee aims to assist the board in advancing the Lets Go platform, which is part of the company's wholly-owned subsidiary, Hong Kong Fuhe Holdings Limited, and its innovation division, Resohealth FZCO [1] - Lets Go is positioned as Reso Health's flagship AI health platform, designed to offer comprehensive, digitally-driven health management solutions to employers, insurance companies, and healthcare institutions [1] - The platform is based on the preventive healthcare philosophy of the traditional Chinese medicine brand "Ye Kai Tai," which has a history of 400 years, integrating traditional medical wisdom with modern AI technology to provide solutions in the global health sector [1] Group 2 - The company is focusing on key emerging markets, including the UAE, East Africa, India, and Southeast Asia, to implement its preventive healthcare ecosystem [1]

Core Insights - The establishment of an Artificial Intelligence Medical Advisory Committee by the company aims to provide strategic guidance and expert insights to the board, facilitating the development of the AI-driven digital health platform LetsGo [1] - The formation of the advisory committee reflects the company's commitment to building a preventive healthcare ecosystem in key emerging markets, including the UAE, East Africa, India, and Southeast Asia [1] Summary by Categories - **Company Initiatives** - The company has formed an Artificial Intelligence Medical Advisory Committee to support the strategic direction of its digital health platform LetsGo [1] - The committee will assist in leveraging AI technology to enhance healthcare services [1] - **Market Focus** - The company is focusing on emerging markets such as the UAE, East Africa, India, and Southeast Asia for its preventive healthcare ecosystem [1] - This initiative indicates a strategic expansion into regions with significant growth potential in healthcare [1]

Group 1 - The core point of the article is that North China Resources (00618) has established an Artificial Intelligence Medical Advisory Committee to provide strategic guidance and expert insights to the company's board, aimed at advancing its AI-driven digital health platform, LetsGo [1] - The advisory committee's formation reflects the company's commitment to building a preventive healthcare ecosystem in key emerging markets, including the UAE, East Africa, India, and Southeast Asia [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 Peking University Resources (Holdings) Company Limited 北 大 資 源（ 控 股 ）有 限 公 司 （於百慕達註冊成立之有限公司） （股份代號：00618） 自願公告 成立人工智能醫療諮詢服務委員會 本公告由北大資源（控股）有限公司（「公司」，及其子公司統稱為「集團」）自願發 佈。 成立人工智能醫療諮詢服務委員會以支持LetsGo平台在新興市場的發展 公司欣然宣佈成立人工智能醫療諮詢服務委員會（「諮詢委員會」），旨在為公司董 事會（「董事會」提供戰略指導和專家見解，協助推動集團的人工智能驅動的數字 健康平台LetsGo的發展，該平台隸屬於集團全資子公司香港富合控股有限公司及 創新部門Resohealth FZCO（「ResoHealth」）。 成立諮詢委員會反映集團致力於在包括阿聯酋、東非、印度和東南亞在內的主要 新興市場建設預防醫療生態系統的承諾。 ...

Core Viewpoint - North China Resources (00618.HK) announced that it will hold a board meeting on November 28, 2025, to approve the interim results for the six months ending September 30, 2025, and to consider the distribution of an interim dividend if applicable [1] Summary by Categories - **Company Announcement** - The company will hold a board meeting on November 28, 2025 [1] - The meeting will focus on approving the interim results for the six months ending September 30, 2025 [1] - The board will also consider the distribution of an interim dividend if applicable [1]